Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer

@inproceedings{Steg2014ProteasomeIR,
  title={Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer},
  author={Adam D. Steg and Mata R. Burke and Hope M. Amm and Ashwini A. Katre and Zachary C. Dobbin and Dae Hoon Jeong and Charles N. Landen},
  booktitle={Oncotarget},
  year={2014}
}
The goal of this study was to determine whether combined targeted therapies, specifically those against the Notch, hedgehog and ubiquitin-proteasome pathways, could overcome ovarian cancer chemoresistance. Chemoresistant ovarian cancer cells were exposed to gamma-secretase inhibitors (GSI-I, Compound E) or the proteasome inhibitor bortezomib, alone and in combination with the hedgehog antagonist, LDE225. Bortezomib, alone and in combination with LDE225, was evaluated for effects on paclitaxel… CONTINUE READING